Inflammation-associated changes in bone homeostasis

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 3, 2012, Pages 188-195

  Scholtysek, Carina ^a   Krönke, Gerhard ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Arthritis; Autoimmune disease; Bone; Immune activation; Inflammation

Indexed keywords

COLONY STIMULATING FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BONE EROSION; BONE HOMEOSTASIS; BONE REMODELING; BONE TURNOVER; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOMYELITIS; PERIODONTAL DISEASE; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 84860455449     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812800392706     Document Type: Review

References (74)

1. House, M.G.; Kohlmeier, L.; Chattopadhyay, N.; Kifor, O.; Yamaguchi, T.; Leboff, MS.; Glowacki, J.; Brown, E.M. Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J. Bone Miner Res., 1997, 12(12), 1959-1970.
2. Karsenty, G.; Wagner, E.F. Reaching a Genetic and Molecular Understanding of Skeletal Development. Dev. Cell, 2002, 2(4), 389-406.
3. Rodan, G.A.; Martin, T.J. Therapeutic approaches to bone diseases. Science, 2000, 289(5484), 1508-1514.
4. Takayanagi, H., OsteoImmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol., 2007, 7(4), 292-304.
5. Arron, J.R.; Choi, Y. OsteoImmunology: Bone versus immune system. Nature, 2000, 408(6812), 535-536.
6. Roodman, G.D. Advances in bone biology: the osteoclast. Endocr. Rev., 1996, 17(4), 308-332.
7. Matsuzaki, K.; Udagawa, N.; Takahashi, N.; Yamaguchi, K.; Yasuda, H.; Shima, N.; Morinaga, T.; Toyama, Y.; Yabe, Y.; Higashio, K.; Suda, T. Osteoclast differentiation factor (odf) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Comm., 1998, 246(1), 199-204.
8. Mikkelsen, H.B.; Thuneberg, L. Op/op mice defective in production of functional colony-stimulating factor-1 lack macrophages in muscularis externa of the small intestine. Cell Tissue Res., 1999, 295(3), 485-493.
9. Yoshida, H.; Hayashi, S.; Kunisada, T.; Ogawa, M.; Nishikawa, S.; Okamura, H.; Sudo, T.; Shultz, L.D.; Nishikawa, S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 1990, 345(6274), 442-444.
10. Kong, Y.Y.; Yoshida, H.; Sarosi, I.; Tan, H.L.; Timms, E.; Capparelli, C.; Morony, S.; Oliveira-dos-Santos, A.J.; Van, G.; Itie, A.; Khoo, W.; Wakeham, A.; Dunstan, C.R.; Lacey, D.L.; Mak, T.W.; Boyle, W.J.; Penninger, J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397(6717), 315-323.
11. Burgess, T.L.; Qian, Y.; Kaufman, S.; Ring, B.D.; Van, G.; Capparelli, C.; Kelley, M.; Hsu, H.; Boyle, W.J.; Dunstan, C.R.; Hu, S.; Lacey, D.L. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts. J. Cell Biol, 1999, 145(3), 527-538.
12. Kong, Y.Y.; Feige, U.; Sarosi, I.; Bolon, B.; Tafuri, A.; Morony, S.; Capparelli, C; Li, J; Elliott, R.; McCabe, S.; Wong, T.; Campagnuolo, G.; Moran, E.; Bogoch, E.R.; Van, G.; Nguyen, L.T.; Ohashi, P.S.; Lacey, D.L.; Fish, E.; Boyle, W.J.; Penninger, J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999, 402(6759), 304-309.
13. Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Lüthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W.J. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell, 1997, 89(2), 309-319.
14. Gori, F.; Hofbauer, L.C.; Dunstan, C.R; Spelsberg, T.C.; Khosla, S.; Riggs, B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology, 2000, 141(12), 4768-4776.
15. Davies, J; Warwick, J; Totty, N.; Philp, R; Helfrich, M.; Horton, M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J. Cell Biol, 1989, 109(4), 1817-1826.
16. Li, Y.P.; Chen, W.; Liang, Y.; Li, E.; Stashenko, P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat. Genet., 1999, 23(4), 447-451.
17. Leisen, J.C.; Duncan, H.; Riddle, J.M.; Pitchford, W.C. The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. J. Rheumatol, 1988, 15, 17-22.
18. Ashton, B.A.; Ashton, I.K.; Marshall, M.J.; Butler, R.C. Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis. Ann. Rheum. Dis., 1993, 52(2), 133-137.
19. Chang, J.S.; Quinn, J.M.; Demaziere, A.; Bulstrode, C.J.; Francis, M.J.; Duthie, R.B.; Athanasou, N.A. Bone resorption by cells isolated from rheumatoid synovium. Ann. Rheum. Dis., 1992, 51(11), 1223-1229.
20. Schett, G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity, 2008, 41(3), 224-229.
21. Redlich, K.; Hayer, S.; Ricci, R.; David, J.P.; Tohidast-Akrad, M.; Kollias, G.; Steiner, G.; Smolen, J.S.; Wagner, E.F.; Schett, G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest., 2002, 110(10), 1419-1427.
22. Pettit, A.R.; Ji, H.; von Stechow, D.; Müller, R.; Goldring, S.R.; Choi, Y.; Benoist, C; Gravallese, E.M. TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis. Am. J. Pathol, 2001, 159(5), 1689-1699.
23. Xia, L.; Kilb, J; Wex, H.; Li, Z.; Lipyansky, A; Breuil, V.; Stein, L; Palmer, J.T.; Dempster, D.W.; Brömme, D. Localization of rat cathepsin k in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin k-activity by peptidyl vinyl sulfones. Biol. Chem., 1999, 380(6), 679-687.
24. Harada, S.-i. and G.A. Rodan, Control of osteoblast function and regulation of bone mass. Nature, 2003, 423(6937), 349-355.
25. Heino, T.J.; Hentunen, T.A; Väänänen, H.K. Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-p: Enhancement by estrogen. J. Cell Biochem., 2002, 85(1), 185-197.
26. Glass, D.A. 2nd.;Bialek, P.; Ahn, J.D.; Starbuck, M.; Patel, M.S.; Clevers, H.; Taketo, M.M.; Long, F.; McMahon, A.P.; Lang, R.A.; Karsenty, G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell, 2005, 8(5), 751-64.
27. Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, M.T.; Martin, T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 1999, 20(3), 345-357.
28. Zhao, C; Irie, N.; Takada, Y.; Shimoda, K.; Miyamoto, T.; Nishiwaki, T.; Suda, T.; Matsuo, K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab., 2006, 4(2), 111-121.
29. McKenna, H.J.; Stocking, K.L.; Miller, R.E.; Brasel, K.; De Smedt, T.; Maraskovsky, E.; Maliszewski, C.R.; Lynch, D.H.; Smith, J.; Pulendran, B.; Roux, E.R.; Teepe, M.; Lyman, S.D.; Peschon, J.J. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood, 2000, 95(11), 3489-3497.
30. Alnaeeli, M.; Park, J.; Mahamed, D.; Penninger, J.M.; Teng, Y.T. Dendritic Cells at the Osteo-Immune Interface: Implications for Inflammation-Induced Bone Loss. J. Bone Mineral Res., 2007, 22(6), 775-780.
31. Neumann, E.; Lefèvre, S.; Zimmermann, B.; Gay, S.; Müller-Ladner, U. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med., 2010, 16(10), 458-468.
32. Lefèvre, S.; Knedla, A.; Tennie, C; Kampmann, A.; Wunrau, C; Dinser, R.; Korb, A.; Schnäker, E.M.; Tarner, I.H.; Robbins, P.D.; Evans, C.H.; Stürz, H.; Steinmeyer, J.; Gay, S.; Schölmerich, J.; Pap, T.; Müller-Ladner, U.; Neumann, E. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med., 2009, 15(12), 1414-1420.
33. Li, Y.; Toraldo, G.; Li, A.; Yang, X.; Zhang, H.; Qian, W.P.; Weitzmann, M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 2007, 109(9), 3839-3848.
34. Kinane, D.F.; Marshall, G.J. Peridonatal manifestations of systemic disease. Australian Dental J., 2001, 46(1), 2-12.
35. Han, X.; Lin, X.; Seliger, A.R; Eastcott, J.; Kawai, T.; Taubman, M.A. Expression of receptor activator of nuclear factor-KB ligand by B cells in response to oral bacteria. Oral Microbiol. Immunol, 2009, 24(3), 190-196.
36. Choi, Y.; Woo, K.M.; Ko, S.H.; Lee Y.J.; Park, S.J.; Kim, H.M.; Kwon, B.S. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8+ T cells. Eur. J. Immunol, 2001, 31(7), 2179-2188.
37. Sato, K.; Takayanagi, H. Osteoclasts, rheumatoid arthritis, and osteoImmunology. Curr Opin Rheumatol, 2006, 18(4), 419-26.
38. Bennett, C.L.; Christie, J.; Ramsdell, F.; Brunkow, M.E.; Ferguson, P.J.; Whitesell, L.; Kelly, T.E.; Saulsbury, F.T.; Chance, P.F.; Ochs, H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet, 2001, 27(1), 20-21.
39. Zaiss, M.M.; Frey, B.; Hess, A.; Zwerina, J.; Luther, J.; Nimmerjahn, F.; Engelke, K.; Kollias, G.; Hünig, T.; Schett, G.; David, J.P. Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol, 2010, 184(12), 7238-7246.
40. Gober H-J, Takayanagi H. The interactions and shared mechanisms of T cells and osteoclasts. Inflamm. Regen., 2009, 29, 239-256.
41. Haworth, C; Brennan, F.M.; Chantry, D.; Turner, M.; Maini, R.N.; Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis, Regulation by tumor necrosis factor-a. Eur. J. Immunol, 1991, 21(10), 2575-2579.
42. Brennan, F.M.; Chantry, D.; Jackson, A.; Maini, R.; Feldmann, M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet, 1989, 2(8657), 244-247.
43. Ritchlin, C.T.; Haas-Smith, S.A.; Li, P.; Hicks, D.G.; Schwarz, E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest., 2003, 111(6), 821-831.
44. Feldmann, M.; Brennan, F.M.; Maini, R. N. Role of Cytokines in rheumatoid arthritis. Ann. Rev. Immunol, 1996, 14, 397-440.
45. Keffer, J.; Probert, L.; Cazlaris, H.; Georgopoulos, S.; Kaslaris, E.; Kioussis, D.; Kollias, G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J., 1991, 10(13), 4025-4031.
46. Simsek, I. TNF inhibitors - new and old agents for rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis., 2010, 68(3), 204-210.
47. Gowen, M.; Wood, D.D.; Ihrie, E.J.; McGuire, M.K.; Russell, R.G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature, 1983, 306(5941), 378-380.
48. Boyce, B.F.; Aufdemorte, T.B.; Garrett, I.R.; Yates, A.J.; Mundy, G.R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology, 1989, 125(3), 1142-1150.
49. Jimi, E.; Nakamura, I.; Duong, L.T.; Ikebe, T.; Takahashi, N.; Rodan, G.A.; Suda T. Interleukin 1 Induces Multinucleation and Bone-Resorbing Activity of Osteoclasts in the Absence of Osteoblasts/Stromal Cells. Exp. Cell Res., 1999, 247(1), 84-93.
50. Arend, W. and J.-M. Dayer, Cytokines and Cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum., 1990, 33(3), 305-315.
51. Schröder, J.M.; Sticherling, M.; Henneicke, H.H.; Preissner, W.C.; Christophers, E. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J. Immunol., 1990, 144(6), 2223-2232.
52. Cid, M.C.; Kleinman, H.K.; Grant, D.S.; Schnaper, H.W.; Fauci, A.S.; Hoffman, G.S. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J. Clin. Invest., 1994, 93(1), 17-25.
53. Gitter, B.D.; Labus, J.M.; Lees, S.L.; Scheetz, M.E. Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha. Immunology, 1989, 66(2), 196-200.
54. Boyce, B.F.; Aufdemorte, T.B.; Garrett, I.R.; Yates, A.J.; Mundy, G.R. TNF-induced structural joint damage is mediated by IL-1. Proc. Nat. Acad. Sci., 2007, 104(28), 11742-11747.
55. Ishimi, Y.; Miyaura, C.; Jin, C.H.; Akatsu, T.; Abe, E.; Nakamura, Y.; Yamaguchi, A.; Yoshiki, S.; Matsuda, T.; Hirano, T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunology, 1990, 145(10), 3297-3303.
56. Greenfield, E.M.; Gornik, S.A.; Horowitz, M.C.; Donahue, H.J.; Shaw, S.M. Regulation of Cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J. Bone Mineral Res., 1993, 8(10), 1163-1171.
57. Ishimi, Y.; Miyaura, C.; Jin, C.H.; Akatsu, T.; Abe, E.; Nakamura, Y.; Yamaguchi, A.; Yoshiki, S.; Matsuda, T.; Hirano, T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol., 1990, 145, 3297-3303
58. Strassmann, G.; Jacob, C.O.; Fong, M.; Bertolini, D.R. Mechanisms of paraneoplastic syndromes of colon-26: Involvement of interleukin 6 in hypercalcemia. Cytokine, 1993, 5(5), 463-468.
59. Axmann, R.; Böhm, C.; Krönke, G.; Zwerina, J.; Smolen, J.; Schett, G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum., 2009, 60(9), 2747-2756.
60. Poli, V.; Balena, R.; Fattori, E.; Markatos, A.; Yamamoto, M.; Tanaka, H.; Ciliberto, G.; Rodan, G.A.; Costantini, F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J., 1994, 13(5), 1189-1196.
61. Klein, B.; Wijdenes, J.; Zhang, X.G.; Jourdan, M.; Boiron, J.M.; Brochier, J.; Liautard, J.; Merlin, M.; Clement, C.; Morel-Fournier, B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 1991, 78(5), 1198-204.
62. Roodman, G.D.; Kurihara, N.; Ohsaki, Y.; Kukita, A.; Hosking, D.; Demulder, A.; Smith, J.F.; Singer, F.R. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest., 1992, 89(1), 46-52.
63. Galli, S.J., M. Grimbaldeston, and M. Tsai, Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol., 2008, 8(6), 478-486.
64. Van bezooijen, R.L.; Farih-Sips, H.C.; Papapoulos, S.E.; Löwik, C.W. Interleukin-17: A new bone acting Cytokine in vitro. J. Bone Mineral Res., 1999, 14(9), 1513-1521.
65. Dudler, J.; Renggli-Zulliger, N.; Busso, N.; Lotz, M.; So, A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann. Rheum. Dis., 2000, 59(7), 529-532.
66. Kotake S.U.N., Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest., 1999, 103(9), 1345-1352.
67. Madsen, O.R., O.H. Sørensen, and C. Egsmose, Bone quality and bone mass as assessed by quantitative ultrasound and dual energy x ray absorptiometry in women with rheumatoid arthritis: relationship with quadriceps strength. Ann. Rheum. Dis., 2002, 61(4), 325-329.
68. Aeberli, D.; Eser, P.; Bonel, H.; Widmer, J.; Caliezi, G.; Varisco, P.A.; Möller, B.; Villiger, P.M. Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study. Arthritis Res. Ther., 2010, 12(3), R119.
69. Boyle, W.J., W.S. Simonet, and D.L. Lacey, Osteoclast differentiation and activation. Nature, 2003, 423(6937), 337-342.
70. Feldmann, M. and R.N. Maini, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol., 2001, 19, 163-196.
71. Miller, P.D. Denosumab: Anti-RANKL antibody. Curr. Osteoporos Rep., 2009, 7(1), 18-22.
72. Somayaji, S.N.; Ritchie, S.; Sahraei, M.; Marriott, I.; Hudson, M.C. Staphylococcus aureus induces expression of receptor activator of nf-{kappa}b ligand and prostaglandin e2 in infected murine osteoblasts. Infect. Immun., 2008, 76(11), 5120-5126.
73. Bostanci, N.; Ilgenli, T.; Emingil, G.; Afacan, B.; Han, B.; Töz, H.; Atilla, G.; Hughes, F.J.; Belibasakis, G.N. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J. Clin. Periodontol., 2007, 34(5), 370-376.
74. Wactawski-Wende, J. Periodontal diseases and osteoporosis: association and mechanisms. Ann. Periodontol., 2001, 6(1), 197-208.